Novo Nordisk A/SNOV
± MixedCompetitionrelevance
Novo is resetting strategy under 'Novo Way' to defend its obesity franchise after losing ground to Eli Lilly, with its Wegovy pill holding ~90% of the U.S. oral-obesity market.
Impact on stocks 2
Biotech & Genomic Medicine▲ · 2 stocks
Novo Nordisk A/S
Eli Lilly and CompanyLLY
▲ PositiveCompetitionrelevance
Lilly's Zepbound and Foundayo are gaining ground on Novo, with Foundayo already capturing over 30% of new U.S. oral-treatment patients.
Theme Impact 1
Off-coverage companies
Related news
Amgen Fair Value Target Rises to US$388.03 as Analysts Split on Pipeline Risks
Amgen's updated analyst model lifted its fair value price target to US$388.03 from a prior US$371.93, with the revenue growth assumption rising to 3.50% from 2.93%, the net profit margin assumption moving to 25.15% from 24.84%, the future P/E multiple changing to 25.1x from 24.6x, and the discount rate shifting to 7.96% from 7.70%. The revision reflects a split analyst view, with UBS, Argus, TD Cowen, Scotiabank and Oppenheimer raising their Amgen price targets into a US$420 to US$460 range on the strength of a strong product portfolio, Q2 beats and higher guidance. Wells Fargo and Piper Sandler lifted their targets to US$435, citing external survey work and prescription data they believe support higher long term sales potential for cholesterol and cardiovascular products such as Repatha and Lipfendra. On the bearish side, HSBC downgraded Amgen to Hold and cut its target to US$425 from US$445, saying the stock price now more closely matches its assessment of fair value with limited near term upside, while BMO Capital shifted to a neutral Market Perform stance even with a higher US$450 target, citing ongoing loss of exclusivity headwinds and a need for more clarity on the competitive profile and sales potential of MariTide.
▼impact 4
Trump to Announce Most Favored Nation Drug Pricing for Medicaid in All 50 States
President Trump will announce on Friday that Medicaid beneficiaries in all 50 states will receive Most Favored Nation pricing discounts on some prescription drugs. The White House Council of Economic Advisers projects the move will generate $27.6B in savings for state governments and $36.6B for the federal government over 10 years, according to Semafor, which broke the news. Trump is also scheduled to meet today with the governors of Arkansas, Mississippi, and South Dakota to discuss progress on lowering drug prices. Separately, an AARP Public Policy Institute report released in August found that applying MFN pricing to the top 10 drugs by Medicare Part D and Part B spending in 2025 would cut Medicare spending on those drugs from $273B to $76B between 2029 and 2033.
▲5
Berenberg Upgrades Eli Lilly to Buy, Sees 21% Upside on Obesity Pipeline
Berenberg upgraded Eli Lilly to buy from hold, with analyst Kerry Holford arguing the stock's roughly 300% rally since its first GLP-1 approval is only the beginning. Holford, the bank's head of global pharmaceutical equity research, set a new price target of $1,400, implying a 21% increase from Thursday's close, and said Lilly offers sales growth through 2030 significantly ahead of peers on solid growth from marketed assets and a significant pipeline contribution. Lilly trades at about 26 times forward earnings, above peers in the S&P 500 Pharmaceuticals Index and five of the so-called Magnificent Seven stocks. She pointed to the pending approval of Foundayo, Lilly's GLP-1 pill for diabetes, as likely to unlock significant demand, and said the success of Zepbound and Mounjaro has let Lilly invest heavily beyond obesity, with roughly $60 billion committed to more than 25 business development deals year-to-date, including Centessa Pharmaceuticals for as much as $7.8 billion, Kelonia Therapeutics for up to $7 billion and AtaiBeckley for $3.8 billion. Holford said this non-obesity pipeline is underappreciated by investors.